Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Required: HER2 (ERBB2) overexpression (ihc 3+ or 2+)

Cannot have received: anti-tumor systemic therapy

Exception: adjuvant or neoadjuvant therapy allowed if completed >= 4 weeks before study and all adverse events recovered to ≤ CTCAE level 1 (except hair loss and pigmentation)

Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation)